Short News


short news

South Korea coronary
stents market

The coronary stents market in South Korea is expected to grow at double digit compound annual growth rate (CAGR) of 11.7% between 2020 and 2025, driven by increasing use of percutaneous coronary interventions (PCI) for the treatment of heart diseases, forecasts GlobalData, a leading data and analytics company. GlobalData's latest report ˜Coronary Stents (Cardiovascular) – Global Market Analysis and Forecast Model (COVID-19 market impact), reveals that drug eluting stents (DES) accounted for more than 95% of the South Korean coronary market in 2020.

Boston Scientific Corp was the leading player in the South Korean coronary stents market in 2020, followed by Abbott Laboratories and Medtronic plc. Together these companies accounted for around 85% of the market in 2020.

Vedant Goswami, Medical Devices Analyst at GlobalData, comments: With about 600,000 population suffering from angina pectoris and myocardial infarction in 2020, there is a strong demand for coronary stenting procedure in South Korea. In addition, the coronary stents market growth in South Korea is driven by improved outcomes of stenting procedures and lower prices. Access to quality healthcare facilities and better screening and diagnosis are expected to further boost the market growth.

Mr. Goswami concludes: The use of DES devices in coronary stenting procedures is quite high in South Korea due to their superior clinical outcomes compared to other stents. This trend is expected to continue in the future mainly due to the decline of bare metal stents usage and long-term clinical trials assessing the safety and effectiveness of bioabsorbable stents (BAS) are still under progress. High cost of BAS compared to DES is also a major factor for increased adoption of DES in South Korea.

Have girls struggled more
than boys during the
COVID-19 pandemic?

In a survey-based study of 523 teens in Iceland, girls reported a greater negative impact of the COVID-19 pandemic on well-being and behavior than boys, and they reported a high level of depressive symptoms.

In the JCPP Advances study, higher depressive symptoms were linked with increased passive social media use and decreased connecting with family members by telephone or social media among girls, and decreased sleeping and increased online gaming among boys.

Contributors to poor mental health included concerns about others contracting COVID-19, changes in daily and school routines, and not seeing friends in person.

The findings suggest that healthcare providers, teachers, and other professionals need to especially monitor depressive symptoms and well-being of girls during COVID-19 and in its aftermath, said lead author Thorhildur Halldorsdottir, PhD, clinical psychologist and assistant professor in the Department of Psychology at Reykjavik University.

Study links metabolic
syndrome to poor health
outcomes in kidney disease

A study published in the Journal of Internal Medicine has uncovered a high prevalence of metabolic syndrome in adults with moderate chronic kidney disease, and found that metabolic syndrome increases their risk of premature death and cardiovascular problems.

Among 5,110 adults in Germany who had chronic kidney disease, 64.3% also had metabolic syndrome. During 6.5 years of follow-up, 605 patients died and 650 experienced major cardiovascular events (such as heart attacks and strokes). Patients with metabolic syndrome had a 26% higher risk of dying and a 48% higher risk of experiencing cardiovascular events. The risk increased steadily with a growing number of metabolic syndrome components, such as increased waist circumference, blood sugar levels, triglycerides, and blood pressure, and decreased HDL cholesterol.

Although our study uncovered a shockingly high frequency of metabolic syndrome in this high-risk patient group, there is a motivating message for our patients: each metabolic syndrome component avoided might considerably decrease the risk for a cardiovascular endpoint or premature death, said senior author Florian Kronenberg, MD, of the Medical University of Innsbruck, in Austria.

© Professional Medical Publications. All rights reserved.